Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Autologous pancreatic islets cells
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Kyslecel
Highest Development Status: Approved Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Orgenesis
Deal Size: $16.3 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 29, 2020
Details:
Following closing of the Transaction, Orgenesis plans to accelerate the commercial scaleup of KYSLECEL throughout the United States and, subject to regulatory and logistical considerations, in international markets as well.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Defibrotide Sodium
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2020
Details:
Enrollment in the study was stopped early based on the recommendation from an IDMC, which concluded it would be highly unlikely to reach statistical significance for the primary endpoint.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
